Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
January 30, 2017 6:45 AM ESTIncyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158  Calithera conference call scheduled today at 8:30 a.m. ET, 5:30 a.m. PT
WILMINGTON, Del. AND SOUTH SAN FRANCISCO, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Incyte Corporation (NASDAQ: INCY) and Calithera... More
